VRDN-001 demonstrates significant improvement in signs and symptoms of Thyroid Eye Disease (TED) after two infusions at 20 mg/kg, consistent with earlier 10 mg/kg results.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.